Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6421
    -0.0004 (-0.07%)
     
  • OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD

    2,406.70
    +8.70 (+0.36%)
     
  • Bitcoin AUD

    100,318.38
    +1,406.59 (+1.42%)
     
  • CMC Crypto 200

    1,334.09
    +21.47 (+1.64%)
     
  • AUD/EUR

    0.6023
    -0.0008 (-0.13%)
     
  • AUD/NZD

    1.0893
    +0.0018 (+0.17%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Stocks - CA, Zogenix Soar in Pre-market, Broadcom, L Brands Sink, Walmart Gains

Stocks in focus in pre-market trade on Thursday
Stocks in focus in pre-market trade on Thursday

Investing.com - Stocks in focus in pre-market trade Thursday:

• CA (CA) stock skyrocketed 18.3% by 8:23 AM ET (12:23 GMT) after Broadcom (AVGO) confirmed that it will acquire the firm for $44.50 per share or $18.9 billion. Broadcom stock sank 9.7%.

• Walmart (WMT) stock gained 0.5% amid a Nikkei report that the firm is looking for buyers for its Japanese supermarket chain Seiyu.

• Delta Air Lines (DAL) stock rose 1.7% as it reported quarterly adjusted earnings per diluted share of $1.77, beating estimates for $1.74. Shares remained higher despite the fact that the airline cut its full-year earnings outlook to a range of $5.35 to $5.70 per share due to an expected $2 billion higher fuel bill for 2018.

ADVERTISEMENT

• L Brands (LB) stock tumbled 7.3% as the firm reported a 3% rise in comparable store sales for the five weeks ending on July 7, slower than the 5% gain seen a month earlier.

• Zogenix Inc (ZGNX) stock soared 21% as it announced positive results from a late stage trial of its drug used in the treatment of epilepsy.

Related Articles

Stock futures rise as big deals, earnings hope dull tariff fears

Rising fares push Delta past profit estimates

Goldman ups Twitter estimates; shares gain 1.9% premarket